NASDAQ:MDGL - Madrigal Pharmaceuticals News Headlines

$105.09
+2.02 (+1.96 %)
(As of 06/20/2019 03:05 AM ET)
Today's Range
$101.27
Now: $105.09
$105.37
50-Day Range
$91.60
MA: $99.96
$107.63
52-Week Range
$89.83
Now: $105.09
$315.00
Volume92,161 shs
Average Volume208,400 shs
Market Capitalization$1.62 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.18

Headlines

Madrigal Pharmaceuticals (NASDAQ MDGL) News Headlines

Source:
DateHeadline
Here’s What Hedge Funds Think About Madrigal Pharmaceuticals, Inc. (MDGL)Here’s What Hedge Funds Think About Madrigal Pharmaceuticals, Inc. (MDGL)
finance.yahoo.com - June 20 at 12:21 AM
Madrigal Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:MDGL)Madrigal Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:MDGL)
www.americanbankingnews.com - June 13 at 6:13 AM
Investors Purchase High Volume of Madrigal Pharmaceuticals Call Options (NASDAQ:MDGL)Investors Purchase High Volume of Madrigal Pharmaceuticals Call Options (NASDAQ:MDGL)
www.americanbankingnews.com - June 13 at 6:13 AM
Madrigal Pharmaceuticals Inc Expected to Post Q2 2019 Earnings of ($1.03) Per Share (NASDAQ:MDGL)Madrigal Pharmaceuticals Inc Expected to Post Q2 2019 Earnings of ($1.03) Per Share (NASDAQ:MDGL)
www.americanbankingnews.com - June 12 at 6:59 AM
Madrigal Pharmaceuticals (NASDAQ:MDGL) Rating Increased to Buy at B. RileyMadrigal Pharmaceuticals (NASDAQ:MDGL) Rating Increased to Buy at B. Riley
www.americanbankingnews.com - June 10 at 8:12 AM
Madrigal Pharmaceuticals to Present at Upcoming Investment ConferencesMadrigal Pharmaceuticals to Present at Upcoming Investment Conferences
finance.yahoo.com - June 4 at 8:51 AM
-$1.03 EPS Expected for Madrigal Pharmaceuticals Inc (MDGL) This Quarter-$1.03 EPS Expected for Madrigal Pharmaceuticals Inc (MDGL) This Quarter
www.americanbankingnews.com - June 1 at 6:12 PM
Madrigal Pharmaceuticals Inc (MDGL) Given Average Rating of "Buy" by BrokeragesMadrigal Pharmaceuticals Inc (MDGL) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 29 at 2:36 AM
Madrigal, Galmed, And Galectin In Phase 3 NASH: The Need For Therapeutic DiversityMadrigal, Galmed, And Galectin In Phase 3 NASH: The Need For Therapeutic Diversity
seekingalpha.com - May 22 at 6:59 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Certain Officers and Directors of Madrigal Pharmaceuticals, Inc.SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Certain Officers and Directors of Madrigal Pharmaceuticals, Inc.
finance.yahoo.com - May 15 at 8:06 PM
If You Had Bought Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock A Year Ago, Youd Be Sitting On A 12% Loss, TodayIf You Had Bought Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock A Year Ago, You'd Be Sitting On A 12% Loss, Today
finance.yahoo.com - May 8 at 7:18 PM
If You Had Bought Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock A Year Ago, You'd Be Sitting On A 12% Loss, TodayIf You Had Bought Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock A Year Ago, You'd Be Sitting On A 12% Loss, Today
finance.yahoo.com - May 8 at 7:18 PM
Madrigal Pharmaceuticals Reports 2019 First Quarter Financial Results and HighlightsMadrigal Pharmaceuticals Reports 2019 First Quarter Financial Results and Highlights
finance.yahoo.com - May 8 at 8:47 AM
Is Madrigal Pharmaceuticals, Inc. (MDGL) A Good Stock To Buy?Is Madrigal Pharmaceuticals, Inc. (MDGL) A Good Stock To Buy?
finance.yahoo.com - May 1 at 7:09 PM
Madrigal Pharmaceuticals Enters Oversold Territory (MDGL)Madrigal Pharmaceuticals Enters Oversold Territory (MDGL)
www.nasdaq.com - April 22 at 5:59 PM
Madrigals MGL-3196: Not Ideal, But Currently The BestMadrigal's MGL-3196: Not Ideal, But Currently The Best
seekingalpha.com - April 17 at 7:04 PM
MGL-3196: Not Ideal, But Currently The BestMGL-3196: Not Ideal, But Currently The Best
seekingalpha.com - April 16 at 7:21 PM
Madrigal And Resmetirom In NASH: Killing Liver FatMadrigal And Resmetirom In NASH: Killing Liver Fat
seekingalpha.com - April 16 at 7:21 PM
Madrigal Pharmaceuticals to Present Additional Analyses of Data from The Phase 2 NASH Study with MGL-3196 (resmetirom) at The International Liver Congress™ 2019Madrigal Pharmaceuticals to Present Additional Analyses of Data from The Phase 2 NASH Study with MGL-3196 (resmetirom) at The International Liver Congress™ 2019
finance.yahoo.com - April 8 at 8:53 AM
Madrigal Pharma launches late-stage study of MGL-3196 in NASHMadrigal Pharma launches late-stage study of MGL-3196 in NASH
seekingalpha.com - March 28 at 9:00 AM
Madrigal Pharmaceuticals Initiates Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic DecompensationMadrigal Pharmaceuticals Initiates Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation
finance.yahoo.com - March 28 at 9:00 AM
Madrigal Pharmaceuticals IncMadrigal Pharmaceuticals Inc
www.bloomberg.com - March 19 at 9:06 AM
Madrigal Pharmaceuticals Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights - GlobeNewswireMadrigal Pharmaceuticals Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights - GlobeNewswire
globenewswire.com - March 1 at 9:20 AM
Madrigal Pharmaceuticals Reports 2018 Fourth Quarter and Full Year Financial Results and HighlightsMadrigal Pharmaceuticals Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights
finance.yahoo.com - February 27 at 8:46 AM
MDGL: Insiders vs. ShortsMDGL: Insiders vs. Shorts
www.nasdaq.com - February 19 at 6:40 PM
Better Buy: Intercept Pharmaceuticals vs. Madrigal PharmaceuticalsBetter Buy: Intercept Pharmaceuticals vs. Madrigal Pharmaceuticals
finance.yahoo.com - February 17 at 6:46 PM
Gilead's (GILD) Late-Stage Study on Liver Disease Drug FailsGilead's (GILD) Late-Stage Study on Liver Disease Drug Fails
finance.yahoo.com - February 12 at 6:20 PM
Viking Therapeutics, Madrigal move up as Gilead liver drug fails to meet goalsViking Therapeutics, Madrigal move up as Gilead liver drug fails to meet goals
seekingalpha.com - February 11 at 6:19 PM
Viking Therapeutics: Anatomy Of A Multi-BaggerViking Therapeutics: Anatomy Of A Multi-Bagger
seekingalpha.com - January 15 at 5:51 PM
Here's Why Viking Therapeutics Slid 32.2% in DecemberHere's Why Viking Therapeutics Slid 32.2% in December
finance.yahoo.com - January 11 at 6:19 PM
Here's Why Viking Therapeutics Skyrocketed 88.4% in 2018Here's Why Viking Therapeutics Skyrocketed 88.4% in 2018
finance.yahoo.com - January 8 at 6:00 PM
Goldman Called 2019 ‘The Year of NASH,’ Others Say Not So Fast - BloombergGoldman Called 2019 ‘The Year of NASH,’ Others Say Not So Fast - Bloomberg
www.bloomberg.com - December 19 at 8:48 AM
Here is What Hedge Funds Think About Madrigal Pharmaceuticals, Inc. (MDGL)Here is What Hedge Funds Think About Madrigal Pharmaceuticals, Inc. (MDGL)
finance.yahoo.com - December 13 at 10:13 AM
3 Beaten-Down Biotech Stocks That Could Bounce Back in 20193 Beaten-Down Biotech Stocks That Could Bounce Back in 2019
finance.yahoo.com - December 12 at 8:45 AM
Here's Why Madrigal Pharmaceuticals Fell 39.4% in NovemberHere's Why Madrigal Pharmaceuticals Fell 39.4% in November
finance.yahoo.com - December 8 at 4:58 PM
Madrigal Pharmaceuticals Inc (MDGL) CEO Paul A Friedman Bought $471,520 of SharesMadrigal Pharmaceuticals Inc (MDGL) CEO Paul A Friedman Bought $471,520 of Shares
finance.yahoo.com - November 24 at 8:33 AM
Pre-Open Movers 11/19: (AKER) (ZAYO) (REN) Higher; (SPB) (XEC) (MDGL) Lower (more...)Pre-Open Movers 11/19: (AKER) (ZAYO) (REN) Higher; (SPB) (XEC) (MDGL) Lower (more...)
www.streetinsider.com - November 19 at 5:01 PM
Viking Has A More Attractive M&A Valuation Than Madrigal, Raymond James Says In UpgradeViking Has A More Attractive M&A Valuation Than Madrigal, Raymond James Says In Upgrade
www.benzinga.com - November 19 at 5:01 PM
US STOCKS ON THE MOVE-Nvidia, Nordstrom, PG&E Corp, FacebookUS STOCKS ON THE MOVE-Nvidia, Nordstrom, PG&E Corp, Facebook
www.nasdaq.com - November 16 at 5:33 PM
US STOCKS ON THE MOVE-PG&E, Chipmakers, Nordstrom, Facebook, Williams-SonomaUS STOCKS ON THE MOVE-PG&E, Chipmakers, Nordstrom, Facebook, Williams-Sonoma
www.nasdaq.com - November 16 at 5:33 PM
Its Going to Be a Big Year for These Pharma CompaniesIt's Going to Be a Big Year for These Pharma Companies
www.bloomberg.com - November 14 at 5:04 PM
Imprimis Pharmaceuticals and Eyenovia among healthcare gainers; Madrigal Pharmaceuticals leads the losersImprimis Pharmaceuticals and Eyenovia among healthcare gainers; Madrigal Pharmaceuticals leads the losers
seekingalpha.com - November 14 at 5:04 PM
Better NASH Stock: Madrigal Pharmaceuticals, Inc. vs. Viking Therapeutics, Inc.Better NASH Stock: Madrigal Pharmaceuticals, Inc. vs. Viking Therapeutics, Inc.
finance.yahoo.com - November 14 at 5:04 PM
Madrigal (MDGL) Says Phase 2 Results for its MGL-3196 in NASH Presented during Presidential Plenary Clinical Session of The Liver MeetingMadrigal (MDGL) Says Phase 2 Results for its MGL-3196 in NASH Presented during Presidential Plenary Clinical Session of The Liver Meeting
www.streetinsider.com - November 13 at 8:32 AM
Phase 2 Results for Madrigals MGL-3196 in...Phase 2 Results for Madrigal's MGL-3196 in...
www.benzinga.com - November 12 at 4:56 PM
Madrigal Pharma up 3% on positive mid-stage MGL-3196 dataMadrigal Pharma up 3% on positive mid-stage MGL-3196 data
seekingalpha.com - November 12 at 4:56 PM
Why Madrigal Pharmaceuticals Stock Slumped in OctoberWhy Madrigal Pharmaceuticals Stock Slumped in October
finance.yahoo.com - November 12 at 4:56 PM
Phase 2 Results for Madrigal’s MGL-3196 in Non-Alcoholic Steatohepatitis (NASH) Presented during Presidential Plenary Clinical Session of The Liver Meeting® 2018Phase 2 Results for Madrigal’s MGL-3196 in Non-Alcoholic Steatohepatitis (NASH) Presented during Presidential Plenary Clinical Session of The Liver Meeting® 2018
finance.yahoo.com - November 12 at 4:56 PM
Madrigal preparing for late-stage testing of experimental NASH treatmentMadrigal preparing for late-stage testing of experimental NASH treatment
finance.yahoo.com - November 12 at 4:56 PM
Madrigal Pharmaceuticals misses by $0.03Madrigal Pharmaceuticals misses by $0.03
seekingalpha.com - November 6 at 8:41 AM
This page was last updated on 6/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel